albendazole has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, H | 2 |
| Sun, H | 2 |
| Zhang, B | 2 |
| Liu, S | 2 |
| Deng, S | 2 |
| Weng, Z | 2 |
| Zuo, B | 2 |
| Yang, J | 2 |
| He, Y | 2 |
| Yue, L | 1 |
| Priotti, J | 1 |
| Baglioni, MV | 1 |
| García, A | 1 |
| Rico, MJ | 1 |
| Leonardi, D | 1 |
| Lamas, MC | 1 |
| Menacho Márquez, M | 1 |
3 other studies available for albendazole and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Topics: Albendazole; Animals; Apoptosis; Cell Movement; Cell Proliferation; Female; Fluorodeoxyglucose F18; | 2020 |
(cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131.
Topics: Albendazole; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Chemoradiotherapy; Dose | 2022 |
Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.
Topics: Albendazole; Animals; Antiparasitic Agents; beta-Cyclodextrins; Biological Availability; Cell Prolif | 2018 |